Latest Content

Oncology clinical trial nurse navigator Elise Curry, RN, explains the impact of the FDA's approval of oral iberdomide for multiple myeloma.

A meta-analysis shows traditional pathology counts fail to predict which patients benefit from adding hormone therapy to postoperative radiation.

The FDA granted accelerated approval to iberdomide with daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Oncology social worker Kelly Dyckman, LCSW, shares key strategies for identifying patient distress, demystifying counseling, and managing trauma.

AMH and INHB testing can identify premenopausal patients with HR+/HER2- breast cancer who may safely avoid chemotherapy, sparing unnecessary toxicity.

Duke Blood Cancer Center's Melissa LaMirand, FNP-C, discusses quad therapies, bispecific workflows, and nursing standardization in multiple myeloma.

Emily M. Beard, BSN, RN, OCN, CBCN, BHCN, discusses the vital role of oncology nurse navigation in addressing barriers to care and improving outcomes in cancer survivorship.

FDA approves Tudriqev-nivolumab for advanced melanoma. Learn key clinical trial data, dosing math, and safety rules for oncology nursing teams.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses patient compliance, side effect management, and screening anxiety in breast cancer care.

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

FDA approves Tudriqev with nivolumab for advanced cutaneous melanoma. Learn about dosing, safety warnings, and trial data for oncology nurses.